Intake of Proton-Pump Inhibitors and Gastric Cancer within the Stomach Cancer Pooling (StoP) Project

Data de publicação:

Autores da FMUP

  • Nuno Miguel De Sousa Lunet

    Autor

Participantes de fora da FMUP

  • Sassano, M
  • Mariani, M
  • Pelucchi, C
  • Morais, S
  • Martín, V
  • Moreno, V
  • Curado, MP
  • Dias-Neto, E
  • Leja, M
  • Gasenko, E
  • La Vecchia, C
  • Boccia, S
  • Pastorino, R

Unidades de investigação

Abstract

Background: A potential association between proton-pump inhibitors (PPI) and gastric cancer remains undefined. Thus, we aimed to evaluate such association within the Stomach cancer Methods: Data from five case-control studies of the StoP Project were included (1,889 cases and 6,517 controls). We assessed the impact of different exposure definitions, specifically any reported use of PPIs and exposure definitions based on the duration of PPI intake. Additionally, we modeled the dose-response relationship between the cumulative duration of PPI intake and gastric cancer. Results: Significant associations between PPI intake and gastric cancer, both overall and in the stratified analyses, were limited to exposure definitions based on short durations of intake. The overall odds ratio (OR) for any reported PPI intake was 1.78 [95% confidence interval (CI): 0.76-4.14]. In the dose-response analysis, the ORs of gastric cancer were found to be higher for short durations of PPI intake (6 months: OR 3.26; 95% CI: 2.40-4.42; one year: OR 2.14; 95% CI: 1.69-2.70; 2 years: OR 1.50; 95% CI: 1.22-1.85; 3 years: OR 1.27; 95% CI: 1.03-1.56), with the association becoming not significant for durations longer than 3 years. Conclusions: Our findings suggest that the observed association between PPIs and gastric cancer might be mainly due to reverse causality. Impact: The results of this study suggest that PPIs area safe thera-peutic choice regarding their effect on the occurrence of gastric cancer. See related commentary by Richman and Leiman, p. 1127

Dados da publicação

ISSN/ISSNe:
1055-9965, 1538-7755

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION  American Association for Cancer Research Inc.

Tipo:
Article
Páginas:
1174-1181
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 4

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • HEALTH-CARE; RISK-FACTOR; DELAY

Campos de estudo

Financiamento

Proyectos asociados

Breast cancer heterogeneity - etiology, clinical management, use of health resources and survival

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2022

Longitudinal Assessment of Cognitive Decline in Breast and Prostate Cancer Survivors

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico (Cognitive Decline) . 2022

Healthcare use among cancer patients and their partners in different phases of the cancer pathway

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2021

Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2020

RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK

Investigador Principal: Nuno Miguel de Sousa Lunet

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação